Results 121 to 130 of about 36,274 (199)

Penile Metastasis From Castration‐Resistant Prostate Cancer: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Penile metastasis from prostate cancer—generally associated with a poor prognosis—is rare and underreported. We report one relevant case. Case Presentation The patient was a 65‐year‐old male with metastatic hormone‐sensitive prostate cancer (prostate‐specific antigen [PSA]: 500 ng/mL) and lung, bone, and lymph node metastases. The
Satoshi Asakura, Yoshihiro Nakagami, Tatsuki Inoue, Yuki Matsui, Kazuhiko Oshinomi, Masakazu Nagata, Takashi Fukagai, Yasuyuki Ohira, Yoshiko Yamochi   +8 more
wiley   +1 more source

SLC3A1 Mitigates Ferroptosis and Promotes Enzalutamide Resistance in Prostate Cancer

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 9, September 2026.
SLC3A1 is a promising therapeutic target for advanced prostate cancer. ABSTRACT Prostate cancer (PCa) remains a leading cause of cancer‐related mortality in aging male, with resistance to enzalutamide (Enza) representing a major therapeutic challenge. This study identifies SLC3A1 as a key driver of Enza resistance.
Peng Liu, Haocheng Zhang, Yuhang Qian, Jiong Zhang, Xiaojun Deng, Bin Sun   +5 more
wiley   +1 more source

Metastasis of Castration-Resistant Prostate Adenocarcinoma to the Lacrimal Gland: A Case Report. [PDF]

Reports (MDPI)
Milic N, Lojanica MV, Ivanovic M, Matijasevic M, Ivanovic S.   +4 more
europepmc   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

Improved Chemosensitivity in Metastatic Castration-Resistant Prostate Cancer: The Synergistic Effects of S-Adenosylmethionine and Cabazitaxel. [PDF]

Cancer Med
Arpino R, Cadoni F, Pagano C, Coppola L, Del Vecchio V, Nigam A, Mosca L, Porcelli M.   +7 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Precision Targeting in Metastatic Castration-Resistant Prostate Cancer: Advancements in Personalized Therapeutics

International Journal of Medical Students
Background:  Castration-resistant prostate cancer continues to be an incurable and aggressive condition. Enzalutamide; an antiandrogen, shows better radiographic progression-free survival and overall survival in men with metastatic castration ...
ALI HASSAN SALIM KIDIYA, Arshiya ummey, Naga Sai Gouthami Gurujala, Srijamya   +3 more
doaj  

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. [PDF]

Mol Oncol
Gordon N, Gallagher PT, Richter OI, Poudel Neupane N, Mandigo AC, McCann JJ, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Schiewer MJ, Shafi AA.   +13 more
europepmc   +1 more source